Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Acquisitions & Divestments: 2016-2024

Historic Change in Acquisitions & Divestments for Zevra Therapeutics (ZVRA) over the last 7 years, with Dec 2024 value amounting to $25.0 million.

  • Zevra Therapeutics' Change in Acquisitions & Divestments rose 504.70% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.2 million, marking a year-over-year increase of 82.70%. This contributed to the annual value of $25.0 million for FY2024, which is 57.71% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Change in Acquisitions & Divestments of $25.0 million as of FY2024, which was down 57.71% from $59.1 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Change in Acquisitions & Divestments peaked at $59.1 million during FY2023, and registered a low of $1.3 million during FY2022.
  • Over the past 3 years, Zevra Therapeutics' median Change in Acquisitions & Divestments value was $25.0 million (recorded in 2024), while the average stood at $28.5 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 4,361.96% in 2023, then crashed by 57.71% in 2024.
  • Zevra Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $1.3 million in 2022, then spiked by 4,361.96% to $59.1 million in 2023, then slumped by 57.71% to $25.0 million in 2024.